Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives $21.36 Average Price Target from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $21.3636.

Several research firms have commented on CMPS. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a report on Monday. Jefferies Financial Group raised Compass Pathways to a “strong-buy” rating in a report on Tuesday, May 5th. Royal Bank Of Canada boosted their target price on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Wolfe Research began coverage on Compass Pathways in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, Maxim Group upped their price objective on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Toronto Dominion Bank raised its position in Compass Pathways by 152.9% in the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after buying an additional 1,529,013 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in Compass Pathways in the 3rd quarter worth about $7,890,000. Nantahala Capital Management LLC boosted its holdings in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in Compass Pathways in the third quarter worth approximately $6,926,000. Finally, Orbimed Advisors LLC purchased a new stake in Compass Pathways in the first quarter worth approximately $6,363,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Up 2.8%

Shares of Compass Pathways stock opened at $13.05 on Friday. The company has a 50-day moving average of $8.86 and a 200 day moving average of $7.35. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -4.14 and a beta of 2.50. Compass Pathways has a 1 year low of $2.25 and a 1 year high of $14.76. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. As a group, sell-side analysts anticipate that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.